Oral Mucositis Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032
Oral Mucositis (OM), also called
stomatitis, is the most common, debilitating complication of cancer
chemotherapy and radiotherapy, characterized by inflammation and ulceration in
the oral cavity caused by the chemotherapeutic drug substances and radiotherapy
used in cancer treatment. Typical manifestations of Oral Mucositis are varying
degrees of erythema, atrophy, ulceration, and mucosa swelling. It has a
significant negative impact on patients’ quality of life (QOL). Potential
complications of OM include pain, increased the risk of local and systemic
infections, bleeding, insufficient food intake, delays in the administration of
radiotherapy and or chemotherapy, a dose reduction of the chemotherapy drugs,
increased the length of hospital stays, associated economic burdens and in some
cases life-threatening infections (septicemia in neutropenic instances).
Mucositis is one of the most generally reported toxicities of mTOR inhibitors,
and in some studies, it was the dose-limiting toxicity. Oral toxicities with
other targeted agents, such as kinase inhibitors and monoclonal antibodies, are
less common. Yet studies have shown a significant incidence of all-grade
mucositis with bevacizumab, erlotinib, sorafenib, and sunitinib.
- The incidence of oral toxicity associated with targeted
agents has been shown to increase as the dose increases. The incidence of
Oral Mucositis (OM) ranges from 590 to 650 cases per 100,000 population in
the USA.
Thelansis’s “Oral Mucositis Market
Outlook, Epidemiology, Competitive
Landscape, and Market Forecast Report – 2021 To 2032" covers disease
overview, epidemiology, drug utilization, prescription share analysis,
competitive landscape, clinical practice, regulatory landscape, patient share,
market uptake, market forecast, and key market insights under the potential Oral
Mucositis treatment modalities options for eight major markets (USA, Germany,
France, Italy, Spain, UK, Japan, and China).
KOLs insights
of Oral Mucositis across 8 MM market from the centre of Excellence/ Public/
Private hospitals participated in the study. Insights around current treatment
landscape, epidemiology, clinical characteristics, future treatment paradigm,
and Unmet needs.
Oral Mucositis Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment